NRC HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS
NRC HEALTH (NRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_992998.htm EXHIBIT 99.1 ex_992998.htm Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com NRC HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS Second quarter TRCV* increased 11% year-over-year to $151.9 million LINCOLN, Nebrask
How this was made
The 30-second read
Why it matters
This is a primary-source earnings release with multiple decision-relevant metrics: TRCV growth, revenue growth, GAAP vs adjusted profitability, operating cash flow/free cash flow, and a newly declared quarterly dividend with a specific payable date.
Market read
Traders can reassess near-term fundamentals using TRCV momentum, adjusted EBITDA strength, and cash flow conversion, and price in the dividend timing.
What to watch
The adjustment items include accelerated vesting and cash bonuses, which can make adjusted earnings look better than underlying cash generation; traders may want to separate operating cash flow quality from accounting adjustments.
Background
The 8-K includes Item 2.02 with Exhibit 99.1 announcing NRC Health’s second quarter 2026 financial results and defining non-GAAP metrics like TRCV and adjusted figures.
Ticker impact
NRC reported Q2 2026 results, including TRCV of $151.9M (+11% YoY), revenue of $35.4M (+4% YoY), and GAAP net loss of $3.3M.
Near-term bias modestly positive if investors focus on TRCV and adjusted EBITDA strength, but GAAP net loss and low free cash flow may cap upside.
TRCV and adjusted EBITDA are supportive, but GAAP loss and limited operating cash flow/free cash flow reduce conviction. Dividend adds some support, yet the article does not provide guidance or a new forward catalyst beyond the quarter results.
Market effects
Provides a datapoint for healthcare experience/market-research software-like vendors on contract value momentum (TRCV) and monetization.
Limited, as the company is US-focused and the filing is company-specific.
Low, as the disclosure is not tied to global macro or international operations.
Counterpoint
Investors may discount TRCV as a non-GAAP leading indicator and focus on GAAP net loss and weak free cash flow, implying monetization or cash conversion risk.
Key entities
- companyNRC Health
NASDAQ-listed healthcare experience improvement solutions provider reporting Q2 2026 results and declaring a quarterly cash dividend.
